Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Altor BioScience, Shenzhen Beike Biotechnology deal

    Altor BioScience Corp., Miramar, Fla. Shenzhen Beike Biotechnology Co. Ltd., Shenzhen, China Business: Cancer Altor granted Shenzhen Beike rights in China to develop and commercialize ALT-803 for human indications. The …

    Published on 9/22/2014
  • AstraZeneca, Eli Lilly deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology Eli Lilly and AstraZeneca partnered to jointly develop and commercialize AZ's AZD3293 worldwide for …

    Published on 9/22/2014
  • Asuragen, J&J deal

    Asuragen Inc., Austin, Texas Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Supply/Service, Genomics Johnson & Johnson's Janssen Diagnostics LLC subsidiary gained worldwide rights to offer next-generation …

    Published on 9/22/2014
  • Boehringer Ingelheim, BeiGene deal

    Boehringer Ingelheim GmbH, Ingelheim, Germany BeiGene Co. Ltd., Beijing, China Business: Cancer, Biomanufacturing Boehringer partnered with BeiGene to manufacture biopharmaceuticals for BeiGene's clinical trials for …

    Published on 9/22/2014
  • C4X Discovery, Takeda deal

    C4X Discovery Ltd., Manchester, U.K. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: High throughput screening C4X partnered with Takeda's Takeda Cambridge Ltd. subsidiary to apply C4X's NMR-based …

    Published on 9/22/2014
  • California Pacific Medical Center Research Institute, Insys deal

    California Pacific Medical Center Research Institute, San Francisco, Calif. Insys Therapeutics Inc. (NASDAQ:INSY), Phoenix, Ariz. Business: Cancer The institute granted Insys an exclusive license to the institute's …

    Published on 9/22/2014
  • Cardiome, Eurolab deal

    Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Eurolab Especialidades Medicinales de Eurofar s.r.l., Buenos Aires, Argentina Business: Cardiovascular Cardiome's Correvio International S.a.r.l. subsidiary …

    Published on 9/22/2014
  • Cempra, Toyama deal

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Toyama Chemical Co. Ltd., Tokyo, Japan Business: Infectious Cempra received a $10 million milestone payment from Toyama under a 2013 deal granting Toyama exclusive rights to …

    Published on 9/22/2014
  • CombiMatrix, Blue Cross Blue Shield deal

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. Blue Cross and Blue Shield Association, Chicago, Ill. Business: Diagnostic CombiMatrix entered into a contract with health insurer Blue Cross Blue Shield of Illinois to …

    Published on 9/22/2014
  • CureVac, Boehringer Ingelheim deal

    CureVac GmbH, Tuebingen, Germany Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cancer CureVac granted Boehringer exclusive, worldwide rights to develop and commercialize CureVac's CV9202. The vaccine is in a …

    Published on 9/22/2014
  • Endo, Auxilium deal

    Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), Chesterbrook, Pa. Business: Musculoskeletal, Genitourinary, Endocrine/Metabolic Endo made an unsolicited bid to …

    Published on 9/22/2014
  • Evotec, CHDI Foundation deal

    Evotec AG (Xetra:EVT), Hamburg, Germany CHDI Foundation Inc., New York, N.Y. Business: Neurology Evotec and CHDI extended through 2017 a 2006 deal under which Evotec is providing CHDI with medicinal chemistry, assay …

    Published on 9/22/2014
  • Five Prime, GlaxoSmithKline deal

    Five Prime Therapeutics Inc. (NASDAQ:FPRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Musculoskeletal GlaxoSmithKline exercised an option under a 2010 deal to gain …

    Published on 9/22/2014
  • Gilead, Cadila Pharmaceuticals, Cipla, Hetero Drugs, Mylan, Ranbaxy, SeQuent Scientific, Strides Arcolab deal

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Cadila Pharmaceuticals Ltd., Ahmedabad, India Cipla Ltd., Mumbai, India Hetero Drugs Ltd., Hyderabad, India Mylan Inc. (NASDAQ:MYL), Canonsburg, Pa. Ranbaxy …

    Published on 9/22/2014
  • Hy BioPharma, Soligenix deal

    Hy BioPharma Inc., Jamison, Pa. Soligenix Inc. (OTCBB:SNGX), Princeton, N.J. Business: Cancer Soligenix acquired SGX301 from Hy BioPharma for up to $14 million, of which about 2% is payable in cash and about 98% is …

    Published on 9/22/2014
  • J&J, Vivus deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Vivus Inc. (NASDAQ:VVUS), Mountain View, Calif. Business: Endocrine/Metabolic Vivus acquired from Johnson & Johnson's Janssen Pharmaceuticals Inc. a group of patents …

    Published on 9/22/2014
  • Lupin, Merck KGaA deal

    Lupin Ltd. (NSE:LUPIN;BSE:500257), Mumbai, India Merck KGaA (Xetra:MRK), Darmstadt, Germany Business: Cardiovascular, Generics, Endocrine/Metabolic Merck partnered with Lupin to develop and commercialize up to 20 drugs …

    Published on 9/22/2014
  • Mela Sciences, Columbia University deal

    Mela Sciences Inc. (NASDAQ:MELA), Irvington, N.Y. Columbia University, New York, N.Y. Business: Diagnostic Mela Sciences signed a research agreement with Columbia University to explore next-generation capabilities and …

    Published on 9/22/2014
  • Memorial Sloan Kettering, Sellas deal

    Memorial Sloan Kettering Cancer Center, New York, N.Y. Sellas Life Sciences Group, Zurich, Switzerland Business: Cancer The center granted Sellas exclusive, worldwide rights to develop and commercialize the center's WT1…

    Published on 9/22/2014
  • Merck, Sun Pharmaceutical deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai, India Business: Autoimmune Merck granted Sun exclusive, worldwide rights to tildrakizumab (MK-…

    Published on 9/22/2014
  • MyoKardia, Sanofi deal

    MyoKardia Inc., San Francisco, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cardiovascular Sanofi and MyoKardia partnered to co-develop MyoKardia's targeted therapeutics for hypertrophic cardiomyopathy…

    Published on 9/22/2014
  • Ophthotech, Novartis deal

    Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Ophthalmic Ophthotech received a $50 million payment from Novartis under a May deal granting the pharma …

    Published on 9/22/2014
  • RegeneRx, Digital Aria deal

    RegeneRx Biopharmaceuticals Inc. (OTCBB:RGRX), Rockville, Md. Digital Aria Co. Ltd., Gyeonggi-do, South Korea Business: Ophthalmic RegeneRx raised $1 million through the sale of 8.3 million shares at $0.12 to G-treeBNT …

    Published on 9/22/2014
  • Sanofi, Intrexon deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Intrexon Corp. (NYSE:XON), Germantown, Md. Business: Other Intrexon partnered with Sanofi's Sanofi Chimie subsidiary to develop an enhanced production process for an …

    Published on 9/22/2014
  • Seattle Genetics, Genmab deal

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Cancer Seattle Genetics granted Genmab rights to use antibody-drug conjugate (ADC) technology with …

    Published on 9/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993